Evolution of Cochleovestibular Schwannomas

Evolution of Cochleovestibular Schwannomas in the Internal Auditory Canal by Volume Measering With aTeslas MRI 3

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04417868

Enrollment

140

Registered

2020-06-05

Start date

2019-01-01

Completion date

2020-07-31

Last updated

2020-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schwannoma

Keywords

schwannoma, cochleovestibular schwannomas, cochleovestibular, intra labyrinthine schwannoma

Brief summary

Investigators want to know the natural history of the vestibular schwannomas: increasing, decreasing or stability, by monitoring more than 3 MRIs during a span of more than 2 years. They will obtain 3 groups: the volume increasing schwannomas which will be the most important group, the schwannomas that will be stable and a small group where the schwannomas will decrease. The secondary purpose is that the investigators want to know the threshold values: a minimum volume under which we are sure that the schwannoma will not increase, a maximum value where it will increase and if its evolution can be correlated to clinical or radiological criteria.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age over 18 years * having a typical vestibular schwannoma diagnosis during the first MRI, having a minimum of 3 internal auditory canal MRIs on the same machine (Signa HDxt, General Electric, Strasbourg, France) ) at the Hôpitaux Universitaires de Strasbourg * patients consenting to participate

Exclusion criteria

* intra-labyrinthical extension * treatment before the 3 MRIs * no injection of gadolinium * atypical diagnosis

Design outcomes

Primary

Measure	Time frame
Presence or absence of intra labyrinthine vestibular nerve tumor using T2 FIESTA	1 hour after the realization of the MRI

Countries

France

Contacts

Primary ContactAïna VENKATASAMY, MD

aina.venkatasamy@chru-strasbourg.fr33 3 88 12 78 65

Backup ContactSaïd CHAYER, PhD, HDR

said.chayer@chru-strasbourg.fr33 3 88 11 66 90

Outcome results